Inspection Record

Cape Drugs — FDA 483 Findings

US FDAInspected 2018-02-21Published 2024-01-17 3 findingsEquipment and facilityMaterial and supplier control

Inspectors Zakaria I GaniyuThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use and cleaning and maintenance.

2Equipment and facility

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

3Material and supplier control

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Cape Drugs company profile — full history US FDA documents, 2024 Go to Findings search